AI Engines For more Details: Perplexity Kagi Labs You
Antiangiogenic Effects: Vatalanib exerts its primary therapeutic effect by inhibiting angiogenesis, which is the process by which new blood vessels are formed. By blocking the activity of tyrosine kinases involved in angiogenesis, vatalanib helps prevent the growth of new blood vessels, particularly those that supply tumors with nutrients and oxygen.
Cancer Treatment: Vatalanib has been studied as a potential treatment for various types of cancer, including solid tumors such as colorectal cancer, lung cancer, and glioblastoma multiforme. By inhibiting tumor angiogenesis, vatalanib may help slow down the growth and spread of cancer cells, thereby potentially improving outcomes for cancer patients.
Anti-Tumor Activity: In preclinical studies and early-phase clinical trials, vatalanib has demonstrated anti-tumor activity in certain types of cancer. It may help reduce tumor size, inhibit metastasis (the spread of cancer to other parts of the body), and improve overall survival rates in some patients.
Combination Therapy: Vatalanib has been investigated as part of combination therapy regimens for cancer treatment. It may be used in combination with other chemotherapy drugs, targeted therapies, or radiation therapy to enhance the effectiveness of treatment and overcome resistance mechanisms.
Side Effects: Like other angiogenesis inhibitors, vatalanib can cause a range of side effects, which may vary depending on the individual and the dose administered. Common side effects may include hypertension (high blood pressure), fatigue, gastrointestinal symptoms (such as nausea, vomiting, diarrhea), proteinuria (presence of protein in the urine), and hematologic abnormalities (such as anemia or thrombocytopenia).
Cardiovascular Effects: Vatalanib has been associated with cardiovascular side effects, including hypertension and cardiac dysfunction. Close monitoring of blood pressure and cardiac function may be necessary during treatment with vatalanib, especially in patients with preexisting cardiovascular conditions.
Drug Interactions: Vatalanib may interact with other medications, including certain chemotherapy drugs and medications that affect blood clotting or platelet function. Healthcare providers should carefully evaluate potential drug interactions before prescribing vatalanib and monitor patients closely for adverse effects.
Clinical Trials: Vatalanib has been studied in clinical trials for various cancer types, both as monotherapy and in combination with other treatments. Results from these trials have provided valuable insights into the efficacy and safety profile of vatalanib, helping to inform its use in clinical practice.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | 0.3 | |
| ADHD | 1.9 | 1.9 | |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 1.4 | 1.4 | |
| Allergies | 1.7 | 0.9 | 0.89 |
| Allergy to milk products | 0.3 | 0.7 | -1.33 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 2.2 | 2.6 | -0.18 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | 0.6 | |
| Ankylosing spondylitis | 1.5 | 1 | 0.5 |
| Anorexia Nervosa | 0.4 | 1.7 | -3.25 |
| Antiphospholipid syndrome (APS) | 0.9 | 0.3 | 2 |
| Asthma | 1.4 | 0.8 | 0.75 |
| Atherosclerosis | 0.9 | 0.9 | 0 |
| Atrial fibrillation | 1.6 | 2.1 | -0.31 |
| Autism | 3.3 | 3.9 | -0.18 |
| Autoimmune Disease | 0.5 | -0.5 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.7 | 0.7 | |
| Bipolar Disorder | 1 | 0.5 | 1 |
| Brain Trauma | 0.8 | -0.8 | |
| Cancer (General) | 0.4 | -0.4 | |
| Carcinoma | 1 | 0.7 | 0.43 |
| Celiac Disease | 1.3 | 1 | 0.3 |
| Cerebral Palsy | 0.3 | 0.8 | -1.67 |
| Chronic Fatigue Syndrome | 1.6 | 2.2 | -0.38 |
| Chronic Kidney Disease | 1.4 | 1.3 | 0.08 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.5 | -0.5 | |
| Chronic Urticaria (Hives) | 1.2 | -1.2 | |
| Coagulation / Micro clot triggering bacteria | 0.4 | 0.5 | -0.25 |
| Cognitive Function | 1.3 | 0.5 | 1.6 |
| Colorectal Cancer | 2.6 | 1.4 | 0.86 |
| Constipation | 0.4 | 0.5 | -0.25 |
| Coronary artery disease | 1 | 1.9 | -0.9 |
| COVID-19 | 2.6 | 4.4 | -0.69 |
| Crohn's Disease | 4.1 | 2.3 | 0.78 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 1.1 | 0.8 | 0.38 |
| Depression | 3.9 | 3.3 | 0.18 |
| Eczema | 0.7 | 0.6 | 0.17 |
| Endometriosis | 0.7 | 0.5 | 0.4 |
| Epilepsy | 0.9 | 1.3 | -0.44 |
| erectile dysfunction | 1 | 1 | |
| Fibromyalgia | 1.6 | 1.5 | 0.07 |
| Functional constipation / chronic idiopathic constipation | 1.7 | 2.5 | -0.47 |
| gallstone disease (gsd) | 1.7 | 0.5 | 2.4 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.7 | |
| Generalized anxiety disorder | 1 | 0.8 | 0.25 |
| Gout | 0.3 | 0.3 | |
| Graves' disease | 0.7 | 0.8 | -0.14 |
| Gulf War Syndrome | 1.2 | -1.2 | |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 1.4 | 0.6 | 1.33 |
| Heart Failure | 1.4 | 1 | 0.4 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hyperglycemia | 0.7 | -0.7 | |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1.3 | 2.3 | -0.77 |
| Hypoxia | 0.7 | 0.6 | 0.17 |
| IgA nephropathy (IgAN) | 0.7 | 3 | -3.29 |
| Inflammatory Bowel Disease | 2.7 | 3.8 | -0.41 |
| Insomnia | 0.3 | 1.1 | -2.67 |
| Intelligence | 0.9 | 0.6 | 0.5 |
| Intracranial aneurysms | 0.7 | 0.7 | |
| Irritable Bowel Syndrome | 2.7 | 2 | 0.35 |
| ischemic stroke | 0.7 | 1.1 | -0.57 |
| Liver Cirrhosis | 2.4 | 1.1 | 1.18 |
| Long COVID | 2.4 | 2.4 | 0 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.3 | 0.3 | |
| ME/CFS with IBS | 0.3 | -0.3 | |
| ME/CFS without IBS | 0.7 | 0.9 | -0.29 |
| Menopause | 0.5 | -0.5 | |
| Metabolic Syndrome | 3 | 2.9 | 0.03 |
| Mood Disorders | 3.8 | 3 | 0.27 |
| Multiple Sclerosis | 0.8 | 3.5 | -3.38 |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 1.3 | -1.3 | |
| Neuropathy (all types) | 1 | -1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.4 | 1.3 | 0.08 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 3.4 | 3 | 0.13 |
| obsessive-compulsive disorder | 2 | 1.8 | 0.11 |
| Osteoarthritis | 1.6 | 0.3 | 4.33 |
| Osteoporosis | 0.8 | 0.3 | 1.67 |
| Parkinson's Disease | 2.2 | 3.2 | -0.45 |
| Polycystic ovary syndrome | 3.8 | 1.1 | 2.45 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.6 | -0.6 | |
| Primary sclerosing cholangitis | 0.7 | 1.7 | -1.43 |
| Psoriasis | 0.6 | 2.9 | -3.83 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.8 | 1.9 | 0.47 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 1.6 | 1.3 | 0.23 |
| scoliosis | 0.3 | -0.3 | |
| Sjögren syndrome | 1 | 1.6 | -0.6 |
| Sleep Apnea | 0.8 | -0.8 | |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 1.3 | 1.3 | 0 |
| Systemic Lupus Erythematosus | 2.3 | 0.7 | 2.29 |
| Tic Disorder | 0.1 | 0.6 | -5 |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 1.3 | 1 | 0.3 |
| Type 2 Diabetes | 3.5 | 3.2 | 0.09 |
| Ulcerative colitis | 1.5 | 4.1 | -1.73 |
| Unhealthy Ageing | 2 | 1.4 | 0.43 |
| Vitiligo | 1.3 | 0.4 | 2.25 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
